Search Results

RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology agreed to start a research collaboration to create antigens for the next-generation vaccines to deliver innovative solutions to unmet medical need in infectious diseases.

Carterra, Inc. and La Jolla Institute for Immunology (LJI) announced today that LJI has acquired a Carterra LSA instrument to enhance its antibody screening and characterization work.

Journal is the official publication of the International Union of Immunological Societies

Equillium, Inc. today announced data presented at the annual La Jolla Immunology Conference.

XNK Therapeutics AB announced its extensive participation at the 8th Annual Innate Killer Summit in La Jolla, San Diego, CA, March 28-30.

Cytocom, Inc., a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced a collaboration agreement to fund research and laboratory facilities at the La Jolla Institute for Immunology, a not-for-profit academic institution and a world leader in immunology research.

Innoviva, Inc. and La Jolla Pharmaceutical Company announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla.

La Jolla Institute for Immunology (LJI) and Kyowa Kirin, Inc. (KKNA), a wholly-owned subsidiary of Kyowa Kirin Co., Ltd (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company, today announced the signing of a new collaboration agreement.

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“La Jolla”) at a price of $6.23 per share (the “Offer Price”).